Listen & Watch

  1. mRNA Update: Beyond Prophylactic Vaccines 10/10/2023

    mRNA-based therapeutics are widely regarded as a “next big thing” in biopharma, but manufacturing them is fraught with complex challenges. Check out this digital event from Bioprocess Online Live featuring a discussion with mRNA process development experts on the front lines of the mRNA therapeutics revolution.

  2. Risk Reduction In mRNA Therapeutic Development 9/13/2023

    mRNA is at an inflection point. To reach its therapeutic potential in chronic, and even rare, disease applications, some biopharmaceutical manufacturing fundamentals must be addressed.

  3. Major Trends In Next-Gen RNA Engineering 6/13/2023

    From tissue specificity to potency and durability, major trends in RNA are developing as the space continues to evolve at record-breaking speed. In June 2023, Cell & Gene Live welcomed Nathaniel Wang, CEO and Co-Founder, Replicate Bioscience and Sam Deutch, EVP of Research and Early Development at Nutcracker Therapeutics for a deep dive into how RNA can accelerate drug development and how the evolution in the scale-up production of novel engineering technologies impacts near- and long-term deployment of new therapies.

  4. Revolutionary Incrementalism: Future-Proofing mRNA Drug Manufacturing 3/28/2023

    Industry experts share go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare mRNA therapeutics companies for the clinic and, eventually, the commercial market.

  5. LNPs & Beyond: Opportunities In RNA Delivery 10/6/2022

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the importance of mRNA/RNA therapeutics. For those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening their applicability, durability, and effectiveness.

  6. The Wider Use Of mRNA To Treat Various Forms Of Cancer & Autoimmune Diseases 9/16/2022

    Each of the diseases discussed are going to be different in the way that it manifests, and the target cell arguably is going to be different as well. Strapps and Kalayoglu break it down disease by disease.

  7. The Cell As The Delivery Vehicle 9/16/2022

    Dr. Murat Kalayoglu, CEO, Cartesian Therapeutics explains that Cartesian ensures that the cells it administers, and therefore the RNA therapeutics that is administers, meet all the specifications the company sets forth in advance. Part of those specifications ensures that there are a certain number of cells that are indeed capable of expressing the RNA into the relevant protein and at certain levels. He explains that they have solved the problem before ever infusing the RNA therapeutic directly into the body, and therefore, the class of therapies Cartesian develops are referred to as RNA cell therapy to distinguish them from conventional RNA therapies, where the RNA is either introduced directly or through nanoparticle.

  8. Cell & Gene Live Audience Q&A 9/16/2022

    During the hour, audience members submitted their questions for our panelists. To no surprise, they asked thoughtful, solid questions on everything from transecting cells with multiple RNA and the challenges associated with chronic dosing of mRNA therapeutics to the regulatory challenges around mRNA cell therapies.

  9. The Not-So-New Challenges Of mRNA Delivery 9/16/2022

    Walter Strapps, Ph.D., CEO of Carver Biosciences states that when it comes to mRNA, the challenges associated with its delivery are anything but new. Indeed, Strapps explains that challenges have existed essentially since the dawn of nucleotide therapeutics in general. “There is a joke within the oligo nucleotide field similar to the real estate industry in that in real estate it’s location, location, location; for all nucleotides it's delivery, delivery, delivery,” says Strapps.

  10. Innovations In mRNA Delivery 9/16/2022

    Learn about the significant history of the work that made mRNA therapeutics and vaccines possible, the broader problem with mRNA therapeutics, and the innovations on the horizon.